Price$0.25-0.00 (-0.85%)
04:45 PM07:45 PM
News · 26 weeks22+100%
2026-04-262026-10-18
Mix790d
- Market5(71%)
- Insider2(29%)
Latest news
25 items- NEWSIGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial DeploymentPOTOMAC, MD / ACCESS Newswire / October 13, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and Artificial Intelligence (AI)-enabled healthcare technologies, today announced the introduction of PRISM, a new application layer designed to bring its patent-pending MINT-AD Alzheimer's AI platform closer to real-world healthcare applications, including early Alzheimer's risk stratification, cognitive health tracking, clinical trial optimization, and personalized brain-health programs. The introduction represents an important expansion of IGC Pharma's Artificial Intelligence and Alzheimer's disease stra
- INSIDERCEO Mukunda Ram gifted 200,000 shares, decreasing direct ownership by 3% to 6,675,563 units (SEC Form 4)4 - IGC Pharma, Inc. (0001326205) (Issuer)
- INSIDERPFO Grimaldi Claudia gifted 150,000 shares, decreasing direct ownership by 4% to 3,271,092 units (SEC Form 4)4 - IGC Pharma, Inc. (0001326205) (Issuer)
- NEWSIGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026POTOMAC, MD / ACCESS Newswire / September 28, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company") today announced it has completed enrollment in its CALMA Phase 2 trial evaluating lead asset, IGC-AD1, for agitation in Alzheimer's dementia. Enrollment complete; final participant dosing expected to conclude in early November; topline results expected Q4 2026CALMA achieved target enrollment with 168 participants randomized, including planned over-enrollment designed to strengthen the evaluable dataset for end-of-treatment, secondary, and exploratory analyses. Following the protocol-defined six-week treatment period, final participant dosing is expected to complete in early November,
- NEWSIGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment ClosurePhase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding POTOMAC, MD / ACCESS Newswire / August 17, 2026 / IGC Pharma, Inc. (NYSE:IGC), a clinical-stage biotechnology company developing therapeutics and AI-enabled tools for Alzheimer's disease, today announced financial results for the second quarter ended June 30, 2026, and provided an update on the Company's lead Alzheimer's program, IGC-AD1. During the second quarter, the Phase 2 CALMA trial of IGC-AD1 reached the Company's previously disclosed 146-patient baseline randomization target. Subsequent to quarter-end, CALMA has continued its final planned over-enrollment phase and is now within
- NEWSIGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline ReadoutPOTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease, today announced that it is strengthening its regulatory, biostatistical, artificial intelligence ("AI")-enabled data science, and strategic pharmaceutical development capabilities as IGC-AD1, the Company's lead Alzheimer's drug candidate, advances toward expected Phase 2 topline results in the fourth quarter of 2026. CALMA has randomized 160 participants to date. IGC Pharma expects to close enrollment after up to additional participants, marking a key final enrollment milestone before patient follow-up,
- NEWSIGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short CampaignPOTOMAC, MD / ACCESS Newswire / July 29, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that it is evaluating potential civil remedies following the federal jury verdict in United States v. Andrew Left, No. 2:24-CR-456, in the United States District Court for the Central District of California. According to the United States Attorney's Office for the Central District of California, Andrew Left, founder of Citron Research, was found guilty of one count of engaging in a securities fraud scheme and 12 counts of securities fraud. The verdict follows a federal indictment that i
- SECIGC Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - IGC Pharma, Inc. (0001326205) (Filer)
- NEWSIGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative WorkflowSeven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development POTOMAC, MD / ACCESS Newswire / July 9, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced it will showcase its artificial intelligence portfolio across seven scientific presentations at the Alzheimer's Association International Conference (AAIC) 2026, taking place July 12-15 in London. IGC Pharma is building computational infrastructure designed to accelerate data integration, pa
- NEWSIGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the CompanySenior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC POTOMAC, MD / ACCESS Newswire / July 7, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Chief Executive Officer Ram Mukunda and Principal Financial Officer Claudia Grimaldi have purchased an aggregate of 4,274,853 shares of IGC common stock directly from the Company at $0.27 per share. The shares were purchased through the cancellation of approximately $1.15 million of outstanding amounts owed by
- SECIGC Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - IGC Pharma, Inc. (0001326205) (Filer)
- INSIDERCEO Mukunda Ram was granted 2,226,475 shares, increasing direct ownership by 48% to 6,875,563 units (SEC Form 4)4 - IGC Pharma, Inc. (0001326205) (Issuer)
- INSIDERPFO Grimaldi Claudia was granted 2,048,378 shares, increasing direct ownership by 149% to 3,421,092 units (SEC Form 4)4 - IGC Pharma, Inc. (0001326205) (Issuer)
- NEWSIGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative WorkflowPatent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London POTOMAC, MD / ACCESS Newswire / June 23, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease and AI-enabled healthcare technologies, today announced the beta version of its proprietary Agentic Harmonization Assistant ("AHA"), an enterprise software platform designed to accelerate the harmonization of fragmented Alzheimer's and aging-related datasets. The announcement comes as IGC advances IGC-AD1, it
- NEWSIGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline AnalysisCompany Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses POTOMAC, MD / ACCESS Newswire / June 11, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company") today announced that its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's dementia has reached the Company's previously disclosed target enrollment of 146 patients, with 146 participants randomized at baseline. The Company's prior enrollment updates described progress toward this 146-patient target. Based on observed and potential attrition between baseline, Week 2, and end-of-treatment assess
- NEWSAscendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 CatalystsPOTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to $5.50 per share. According to Ascendiant, the updated report highlights the Company's clinical progress and states that additional clinical data and progress in 2026 could serve as strong catalysts for IGC Pharma's stock.IGC Pharma's lead program, IGC-AD1, is currently being evaluated in the Phase 2 CALMA clinical trial for agitation associated with Alzheimer's disease
- SECIGC Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - IGC Pharma, Inc. (0001326205) (Filer)
- NEWSIGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline AnalysisApproximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis POTOMAC, MD / ACCESS Newswire / June 2, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the addition of the Icahn School of Medicine at Mount Sinai in New York as a clinical site in the Company's Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease. The addition of Mount Sinai comes as CALMA advances toward completion, with approximately 80% of targeted participants having completed trial participati
- NEWSIGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment- Continued Advancement of CALMA Phase 2 Trial - POTOMAC, MD / ACCESS Newswire / May 19, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics and artificial intelligence ("AI-enabled") tools for Alzheimer's disease ("AD"), today announced the filing of its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission ("SEC") for the quarter ended March 31, 2026. "During the first quarter, we continued to execute against our core priorities by advancing CALMA, expanding our clinical site network, and strengthening the AI and intellectual property components of our Alzheimer's strategy with disciplined capi
- SECSEC Form 10-Q filed by IGC Pharma Inc.10-Q - IGC Pharma, Inc. (0001326205) (Filer)
- NEWSIGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau ConferenceResearch highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development. POTOMAC, MD / ACCESS Newswire / May 15, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that it will present new Tau-PET biomarker research at the 2026 Global Tau Conference, taking place May 14-15, 2026, at the Grand Hyatt Washington in Washington, D.C., and online. The poster presentation, titled "Shannon Entropy of Tau-PET Spreading Patterns Predict Alzheimer's Disease Progression in Amyloid-Positive APOE4 Carriers," ev
- NEWSIGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment PhaseOutreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion POTOMAC, MD / ACCESS Newswire / April 28, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced its participation in the caregiver-focused podcast Autumn Is Here, as part of its broader effort to increase awareness of agitation associated with Alzheimer's disease and support patient engagement in its ongoing Phase 2 CALMA clinical trial, which has recently reached approximately 80% patient enrollment and is advancing toward completion. The episode featured Margarita Veneg
- NEWSIGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward CompletionBehavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the addition of Kerwin Medical Center in Dallas, Texas as a clinical site in the Company's Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's disease. The Company recently reported approximately 80% enrollment in CALMA and continues to advance toward enrollment completion. The addition comes as the CALMA trial advances through its final phase of en
- SECIGC Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - IGC Pharma, Inc. (0001326205) (Filer)
- NEWSIGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in DementiaAuthorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion POTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that on April 9, 2026, it received authorization in Colombia to synthesize, formulate, and conduct development activities involving psilocybin at its research and development facility in Bogotá. The authorization, granted under the oversight of the Fondo Nacional de Estupefacientes (FNE), provides IGC Pharma with a regulated capability to work wit
IGC FAQ
5 questionsWhat does IGC Pharma Inc. do?
India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. The company operates through two segments, Infrastructure Business, and Life Sciences. It buys and sells infrastructure commodities, such as steel, wooden doors, marble, and tiles; rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts. The company also develops cannabinoid-based products and therapies, such as Hyalolex for the treatment of patients from anxiety, agitation, dementia, depression, and sleep disorder diseases; hemp-based CBD...Where does IGC stock trade?
IGC Pharma Inc. (IGC) is listed on AMEX.What sector and industry is IGC in?
IGC Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to IGC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IGC side-by-side with any of them on Quantisnow.How can I track IGC on Quantisnow?
Quantisnow aggregates IGC Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IGC to receive live email and push alerts on every new disclosure.